Literature DB >> 31682908

Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study.

Javed Butler1, Stephen J Greene2, Svati H Shah3, Sanjiv J Shah4, Kevin J Anstrom5, Raymond J Kim3, Andreas P Kalogeropoulos6, Eric J Velazquez7, Adrian F Hernandez2, Patrice Desvigne-Nickens8, Rebecca Scherzer9, Priscilla Y Hsue10, Eugene Braunwald11.   

Abstract

BACKGROUND: Diastolic dysfunction (DD) is common and occurs at an earlier age among human immunodeficiency virus-infected (HIV+) individuals, but the mechanisms and consequences of DD among HIV+ individuals are unclear. METHODS AND
RESULTS: The Characterization of Heart Function on Antiretroviral Therapy (CHART) study was a multicenter cross-sectional case-control study of treated and virally suppressed HIV+ individuals with (DD+) and without DD (DD-). All patients had normal ejection fraction (>50%), no significant valvular disease, and no history of coronary revascularization or persistent atrial fibrillation. Overall, 94 DD+ and 101 DD- patients were included. DD+ patients were older with higher body mass index (BMI) and more likely to have hypertension, renal dysfunction, and dyslipidemia. Groups were similar with respect to sex, race, CD4 count, and HIV RNA copies. N-terminal pro-B-type natriuretic peptide levels (median 36 [23, 85] vs 26 [12, 49] pg/mL, P < .01) and high-sensitivity troponin I (3.6 [2.6, 5.1] vs 2.5 [1.8, 3.5] pg/mL, P < .01) were higher among DD+ patients. The latter had similar left atrial size, but increased stiffness (conduit strain: 23.5 [17.5, 36.9] vs 30.0 [22.9, 37.0], P < .01) and impaired relaxation (reservoir strain: 39.7 [32.0, 58.0] vs 45.9 [37.0, 60.6], P = .04). On cardiac magnetic resonance, the prevalence of focal fibrosis was higher among DD+ patients (19.0% vs 5.3%, P < .01). DD+ patients demonstrated higher levels of carboxyl-terminal telopeptide of collagen type I (P = .04), and trends toward higher interleukin-6 and oxidized low-density lipoprotein levels (P ≤ .08). Kansas City Cardiomyopathy Questionnaire physical limitation (87.1±21.4 vs 93.1±18.1, P = .01) and symptom frequency scores were lower among DD+ patients (86.0±21.5 vs 92.5±16.8, P = .01).
CONCLUSIONS: In this contemporary HIV+ population receiving antiretroviral therapy, DD was associated with multiple alterations in cardiac structure and function, including myocardial fibrosis and left atrial abnormalities, and worse quality of life. Further studies are needed to assess longitudinal changes in these parameters and their potential as therapeutic targets to prevent progressive cardiac remodeling and dysfunction in HIV.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiretroviral therapy; diastolic dysfunction; human immunodeficiency virus; myocardial fibrosis

Year:  2019        PMID: 31682908      PMCID: PMC7195219          DOI: 10.1016/j.cardfail.2019.10.011

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  25 in total

1.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  Circulation       Date:  2013-06-05       Impact factor: 29.690

2.  Short-term and long-term cardiovascular risk, metabolic syndrome and HIV in Tanzania.

Authors:  Justin R Kingery; Yona Alfred; Luke R Smart; Emily Nash; Jim Todd; Mostafa R Naguib; Jennifer A Downs; Samuel Kalluvya; Johannes B Kataraihya; Robert N Peck
Journal:  Heart       Date:  2016-04-22       Impact factor: 5.994

3.  HIV patients have impaired diastolic function that is not aggravated by anti-retroviral treatment.

Authors:  Ricardo Fontes-Carvalho; Jennifer Mancio; Acúrcio Marcos; Francisco Sampaio; Margarida Mota; Francisco Rocha Gonçalves; Vasco Gama; Ana Azevedo; Adelino Leite-Moreira
Journal:  Cardiovasc Drugs Ther       Date:  2015-02       Impact factor: 3.727

4.  Mortality rate in patients with diastolic dysfunction and normal systolic function.

Authors:  Carmel M Halley; Penny L Houghtaling; Mazen K Khalil; James D Thomas; Wael A Jaber
Journal:  Arch Intern Med       Date:  2011-06-27

5.  Abnormal Myocardial Function Is Related to Myocardial Steatosis and Diffuse Myocardial Fibrosis in HIV-Infected Adults.

Authors:  Diana K Thiara; Chia Ying Liu; Fabio Raman; Sabrina Mangat; Julia B Purdy; Horacio A Duarte; Nancyanne Schmidt; Jamie Hur; Christopher T Sibley; David A Bluemke; Colleen Hadigan
Journal:  J Infect Dis       Date:  2015-05-11       Impact factor: 5.226

6.  Impact of HIV infection on diastolic function and left ventricular mass.

Authors:  Priscilla Y Hsue; Peter W Hunt; Jennifer E Ho; Husam H Farah; Amanda Schnell; Rebecca Hoh; Jeffrey N Martin; Steven G Deeks; Ann F Bolger
Journal:  Circ Heart Fail       Date:  2009-11-20       Impact factor: 8.790

Review 7.  Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study.

Authors:  Javed Butler; Andreas P Kalogeropoulos; Kevin J Anstrom; Priscilla Y Hsue; Raymond J Kim; Rebecca Scherzer; Sanjiv J Shah; Svati H Shah; Eric J Velazquez; Adrian F Hernandez; Patrice Desvigne-Nickens; Eugene Braunwald
Journal:  J Card Fail       Date:  2018-03-02       Impact factor: 5.712

8.  Inflammation, coagulation and cardiovascular disease in HIV-infected individuals.

Authors:  Daniel A Duprez; Jacqueline Neuhaus; Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Daniel Nixon; Nicholas I Paton; Ronald J Prineas; James D Neaton
Journal:  PLoS One       Date:  2012-09-10       Impact factor: 3.240

9.  Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.

Authors:  Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton
Journal:  PLoS Med       Date:  2008-10-21       Impact factor: 11.069

10.  Increased pericardial fat accumulation is associated with increased intramyocardial lipid content and duration of highly active antiretroviral therapy exposure in patients infected with human immunodeficiency virus: a 3T cardiovascular magnetic resonance feasibility study.

Authors:  Mariana Diaz-Zamudio; Damini Dey; Troy LaBounty; Michael Nelson; Zhaoyang Fan; Lidia S Szczepaniak; Bill Pei-Chin Hsieh; Ronak Rajani; Daniel Berman; Debiao Li; Rohan Dharmakumar; W David Hardy; Antonio Hernandez Conte
Journal:  J Cardiovasc Magn Reson       Date:  2015-10-31       Impact factor: 5.364

View more
  7 in total

Review 1.  Ectopic Fat and Cardiac Health in People with HIV: Serious as a Heart Attack.

Authors:  Ana N Hyatt; Jordan E Lake
Journal:  Curr HIV/AIDS Rep       Date:  2022-08-13       Impact factor: 5.495

2.  Association of HIV Infection With Cardiovascular Pathology Based on Advanced Cardiovascular Imaging: A Systematic Review.

Authors:  Jonathan A Hudson; Edith D Majonga; Rashida A Ferrand; Pablo Perel; Shirjel R Alam; Anoop S V Shah
Journal:  JAMA       Date:  2022-09-13       Impact factor: 157.335

Review 3.  Cardiometabolic Complications in Youth With Perinatally Acquired HIV in the Era of Antiretroviral Therapy.

Authors:  Sahera Dirajlal-Fargo; Grace A McComsey
Journal:  Curr HIV/AIDS Rep       Date:  2021-10-15       Impact factor: 5.495

4.  High rate of left ventricular hypertrophy on screening echocardiography among adults living with HIV in Malawi.

Authors:  Risa M Hoffman; Florence Chibwana; Ben Allan Banda; Daniel Kahn; Khumbo Gama; Zachary P Boas; Mayamiko Chimombo; Chiulemu Kussen; Judith S Currier; Dan Namarika; Joep van Oosterhout; Sam Phiri; Agnes Moses; Jesse W Currier; Hitler Sigauke; Corrina Moucheraud; Tim Canan
Journal:  Open Heart       Date:  2022-05

5.  Subclinical Left Ventricular Systolic Dysfunction in HIV Patients: Prevalence and Associations with Carotid Atherosclerosis and Increased Adiposity.

Authors:  Eleni Athanasiadi; Maria Bonou; Dimitrios Basoulis; Chris J Kapelios; Constantina Masoura; Marina Skouloudi; Sophie Mavrogeni; Constantina Aggeli; Mina Psichogiou; John Barbetseas
Journal:  J Clin Med       Date:  2022-03-24       Impact factor: 4.241

6.  Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection.

Authors:  Matthew S Durstenfeld; Michael J Peluso; J Daniel Kelly; Sithu Win; Shreya Swaminathan; Danny Li; Victor M Arechiga; Victor Zepeda; Kaiwen Sun; Shirley Shao; Christopher Hill; Mireya I Arreguin; Scott Lu; Rebecca Hoh; Viva Tai; Ahmed Chenna; Brandon C Yee; John W Winslow; Christos J Petropoulos; John Kornak; Timothy J Henrich; Jeffrey N Martin; Steven G Deeks; Priscilla Y Hsue
Journal:  JCI Insight       Date:  2022-05-23

7.  mTOR regulation of metabolism limits LPS-induced monocyte inflammatory and procoagulant responses.

Authors:  Nina C Lund; Yetunde Kayode; Melanie R McReynolds; Deanna C Clemmer; Hannah Hudson; Isabelle Clerc; Hee-Kyung Hong; Jason M Brenchley; Joseph Bass; Richard T D'Aquila; Harry E Taylor
Journal:  Commun Biol       Date:  2022-08-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.